Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

被引：7

作者：

Roussel, Murielle ^{[1
,2
]}

Hebraud, Benjamin ^{[1
,2
]}

Hulin, Cyrille ^{[3
]}

Leleu, Xavier ^{[4
]}

Facon, Thierry ^{[5
]}

Boyle, Eileen ^{[6
]}

Touzeau, Cyrille ^{[7
]}

Pegourie, Brigitte ^{[8
]}

Perrot, Aurore ^{[9
,10
]}

Stoppa, Anne-Marie ^{[11
]}

Marolleau, Jean-Pierre ^{[12
]}

Moreau, Philippe ^{[13
]}

Avet-Loiseau, Herve ^{[14
]}

Devlamynck, Laure ^{[15
]}

Lauwers-Cances, Valerie ^{[15
]}

Attal, Michel ^{[1
,2
]}

机构：

[1] Inst Univ Canc, Toulouse, France

[2] Univ Hosp, Toulouse, France

[3] Hop Haut Leveque, Dept Hematol, Pessac, France

[4] CHU Poitiers, Serv Hematol & Therapie Cellulaire, Poitiers, France

[5] Hop Claude Huriez, Hosp Huriez, Serv Malad Sang, Lille, France

[6] CHU Lille, Dept Hematol, Lille, France

[7] CHU Nantes, Nantes, France

[8] Ctr Hosp Univ CHU Grenoble, Dept Hematol, Grenoble, France

[9] Hop Brabois, Vandoeuvre Les Nancy, France

[10] Univ Hosp, Dept Hematol, Vandoeuvre Les Nancy, France

[11] Inst Paoli Calmettes, Marseille, France

[12] Amiens Univ Hosp, Dept Hematol, Amiens, France

[13] Univ Hosp Hotel Dieu, Clin Hematol, Nantes, France

[14] IUC T Oncopole, Unite Genom Myelome, Toulouse, France

[15] CHU Toulouse, Serv Epidemiol, USMR, Toulouse, France

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-123184

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3159

引用

页数：4

共 36 条

[11] Comparative Effectiveness of All-Oral Ixazomib-lenalidomide-dexamethasone (IRd) Following Bortezomib (V)-based Induction Versus Continued V-based Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Lee, Hans C.
Costello, Caitlin C.
Birhiray, Ruemu E.
Suman, Kambhampati
Joshua, Richter
Rafat, Abonour
Kim, Yong J.
Kaili, Ren
Stull, Dawn M.
Dasha, Cherapenov
Kimberley, Bogard
Noga, Stephen J.
Saulius, Girnius
Robert., Rifkin
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S8 - S9
[12] Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pboRd) in the Phase 3 TOURMALINE-MM2 Trial
Richardson, Paul G.
Facon, Thierry
Venner, Christopher P.
Bahlis, Nizar J.
Offner, Fritz
White, Darrell
Karlin, Lionel
Benboubker, Lotfi
Rigaudeau, Sophie
Voog, Eric
Yoon, Sung-Soo
Suzuki, Kenshi
Shibayama, Hirohiko
Zhang, Xiaoquan
Kumar, Arun
Twumasi-Ankrah, Philip
Labotka, Richard
Rifkin, Robert M.
Lonial, Sagar
Kumar, Shaji
Rajkumar, S. Vincent
Moreau, Philippe
BLOOD, 2021, 138
[13] A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)
Berdeja, Jesus G.
Gregory, Tara K.
Kambhampati, Suman
Anz, Bertrand M., III
Tarantolo, Stefano R.
Meluch, Anthony A.
Matous, Jeffrey V.
BLOOD, 2019, 134
[14] All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
Touzeau, Cyrille
Perrot, Aurore
Roussel, Murielle
Karlin, Lionel
Benboubker, Lotfi
Jacquet, Caroline
Mohty, Mohamad
Facon, Thierry
Manier, Salomon
Chretien, Marie-Lorraine
Tiab, Mourad
Hulin, Cyrille
Leleu, Xavier
Loiseau, Herve Avet
Dejoie, Thomas
Planche, Lucie
Attal, Michel
Moreau, Philippe
HAEMATOLOGICA, 2022, 107 (07) : 1693 - 1697
[15] Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)
Ishida, Tadao
Ozaki, Shuji
Kimura, Hideo
Kubo, Koumei
Sunami, Kazutaka
Takezako, Naoki
Fujita, Hiroyuki
Hayashi, Toshiaki
Kiguchi, Toru
Kobayashi, Takeshi
Yamamoto, Satoshi
Takamatsu, Hiroyuki
Kosugi, Hiroshi
Ohta, Kensuke
Sakai, Rika
Handa, Hiroshi
Hisatomi, Takashi
Abe, Yu
Sasaki, Ko
Omoto, Eijiro
Murakami, Hirokazu
Shimizu, Kazuyuki
BLOOD, 2017, 130
[16] A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
Silvennoinen, Raija Helena
Waage, Anders
Peceliunas, Valdas
Schjesvold, Fredrik
Mdphd
Anttila, Pekka
Saily, Marjaana
Putkonen, Mervi
Carlson, Kristina
Haukaas, Einar
Sankelo, Marja
Partanen, Anu
Szatkowski, Damian L.
Hansson, Markus
Marttila, Anu
Ahlberg, Lucia
Axelsson, Per
Lauri, Birgitta
Mikkola, Maija Helena
Karlsson, Conny
Abelsson, Johanna
Ahlstrand, Erik
Sikio, Anu
Klimkowska, Monika
Matuzeviciene, Reda
Fenstad, Mona Hoysaeter
Ilveskero, Sorella
Nahi, Hareth
BLOOD, 2020, 136
[17] Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study
Roussel, Murielle
Avet-Loiseau, Herve
Moreau, Philippe
Huynh, Anne
Benboubker, Lotfi
Hulin, Cyrille
Marit, Gerald
Leleu, Xavier
Pegourie, Brigitte
Fruchart, Christophe
Caillot, Denis
Stoppa, Anne-Marie
Facon, Thierry
Harousseau, Jean-Luc
Attal, Michel
BLOOD, 2010, 116 (21) : 274 - 275
[18] Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant
Ocio, Enrique M.
Rodriguez Otero, Paula
Bringhen, Sara
Oliva, Stefania
Nogai, Axel
Attal, Michel
Moreau, Philippe
Kanagavel, Dheepak
Fitzmaurice, Thomas F.
Wu, Junlong
Martinez Lopez, Joaquin
BLOOD, 2018, 132
[19] Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.
Ishida, Tadao
Kimura, Hideo
Kubo, Koumei
Sunami, Kazutaka
Ozaki, Shuji
Takezako, Naoki
Handa, Hiroshi
Kosugi, Hiroshi
Murakami, Hirokazu
Shimizu, Kazuyuki
BLOOD, 2015, 126 (23)
[20] Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for Newly Diagnosed Multiple Myeloma (NDMM) Patients Not Eligible for Autologous Stem Cell Transplant: The Double-Blind, Placebo-Controlled, Phase 3 TOURMALINE-MM2 Trial
Facon, Thierry
Venner, Christopher P.
Bahlis, Nizar J.
Attal, Michel
Offner, Fritz
White, Darrell J.
Karlin, Lionel
Benboubker, Lotfi
Rigaudeau, Sophie
Rodon, Philippe
Voog, Eric
Yoon, Sung-Soo
Suzuki, Kenshi
Shibayama, Hirohiko
Zhang, Xiaoquan
Yung, Godwin
Rifkin, Robert M.
Moreau, Philippe
Lonial, Sagar
Kumar, Shaji K.
Richardson, Paul G.
Rajkumar, S. Vincent
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S307 - S308

← 1 2 3 4 →